Aardvark Raises $29M, Planning Phase 2 Trial of ARD-101 in Treating PWS

Aardvark Raises $29M, Planning Phase 2 Trial of ARD-101 in Treating PWS

302404

Aardvark Raises $29M, Planning Phase 2 Trial of ARD-101 in Treating PWS

Aardvark Therapeutics has raised $29 million in financing to help support three planned Phase 2 clinical trials of its lead compound, ARD-101, an investigational therapy for Prader-Willi syndrome (PWS) and other disorders. Financing was led by Sorrento Therapeutics, with participation from other investors and support from the Foundation for Prader-Willi Research (FPWR). “The Foundation for Prader Willi Research is excited to partner with Aardvark to launch their Phase 2 trial in Prader Willi Syndrome (PWS) later…

You must be logged in to read/download the full post.